ABOUT US

Our Strategy

Saniona Icon blue

Saniona’s focus is on the discovery, development and delivery of proprietary product candidates for the treatment of rare diseases with high unmet medical need.

INVESTMENT RATIONALE

1. Tesomet: positive Phase 2 data in two rare disorders

Hypothalamic obesity (HO) – Phase 2b study expected to begin H2 2021

Prader-Willi syndrome (PWS) – Phase 2b study expected to begin H2 2021

2. Proprietary ion-channel drug discovery engine driving pipeline

SAN711: For rare neuropathic disorders, in Phase 1

SAN903: For rare inflammatory/fibrotic disorders (e.g. IPF), in preclinical

Library: 20,000 proprietary ion channel modifiers

3. Validation from multiple strategic partnerships
Medix logo Boehringer Ingelheim logo
Medix:
Tesofensine for obesity
Novartis:
CAD-1883 for movement disorders
Boehringer Ingelheim:
Novel target for schizophrenia
3. Validation from multiple strategic partnerships

Medix logo
Medix:
Tesofensine for obesity

 


Novartis:
CAD-1883 for movement disorders

 

Boehringer Ingelheim logo
Boehringer Ingelheim:
Novel target for schizophrenia
4. Well-funded to drive current operating plan into H2 2022

Raised USD 65 million – Directed issue of shares (Aug 2020)

Strong institutional support – RA Capital, Pontifax Venture Capital, New Leaf Venture Partners and others

Why rare diseases?

We made the strategic decision to focus on rare diseases because of the tremendous unmet need: there are an estimated 7,000 rare diseases, and less than 10% have FDA-approved treatments. Additionally, clinical trials and regulatory reviews of medicines for rare diseases can potentially require less time and/or less financial investment than in more common disorders, and the commercial infrastructure required to serve rare patient populations is generally smaller, making rare diseases better aligned with Saniona’s capabilities.

Why develop our own molecules?

We made the strategic decision to recruit the expertise and build the capabilities to develop and eventually commercialize our proprietary molecules ourselves, rather than through partnerships, as we believe this strategy can provide the most long-term value to patients and shareholders.